Elite in Chronic B-Cell Leukemia (CBCL)

Barbara F. Eichhorst

Kerpener Str. 62, 
Koeln, NW, DE 
Elite in Chronic B-Cell Leukemia (CBCL)
Kerpener Str. 62, 
Koeln, NW, DE 
OverviewLocationsClinical Research

Overview

Barbara Eichhorst practices in Koeln, Germany. Ms. Eichhorst is rated as an Elite expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), and Leukemia.

Her clinical research consists of co-authoring 184 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 169 articles and participated in 1 clinical trial in the study of Chronic B-Cell Leukemia (CBCL).

Gender
Female

Locations

Kerpener Str. 62, Koeln, NW 50937, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3 Multicenter, Randomized, Prospective, Open-label Trial of Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab Plus Venetoclax (RVe) Versus Obinutuzumab (GA101) Plus Venetoclax (GVe) Versus Obinutuzumab Plus Ibrutinib Plus Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
A Phase 3 Multicenter, Randomized, Prospective, Open-label Trial of Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab Plus Venetoclax (RVe) Versus Obinutuzumab (GA101) Plus Venetoclax (GVe) Versus Obinutuzumab Plus Ibrutinib Plus Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
Enrollment Status: Completed
Publish Date: December 30, 2024
Intervention Type: Drug, Biological
Study Drugs: Fludarabine, Cyclophosphamide, Rituximab, Ibrutinib, Bendamustine, Venetoclax, Obinutuzumab, Ibrutinib
Study Phase: Phase 3

184 Total Publications

Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.
Journal: Leukemia
Published: May 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Eichhorst's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile